Trust Co. of Vermont Sells 41,031 Shares of Pfizer Inc. (NYSE:PFE)

Trust Co. of Vermont cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 282,485 shares of the biopharmaceutical company's stock after selling 41,031 shares during the period. Trust Co. of Vermont's holdings in Pfizer were worth $7,158,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sage Mountain Advisors LLC boosted its stake in Pfizer by 7.3% during the fourth quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company's stock valued at $546,000 after buying an additional 1,404 shares during the last quarter. Penobscot Investment Management Company Inc. lifted its stake in shares of Pfizer by 2.7% in the 1st quarter. Penobscot Investment Management Company Inc. now owns 95,301 shares of the biopharmaceutical company's stock valued at $2,415,000 after purchasing an additional 2,527 shares during the last quarter. Brighton Jones LLC lifted its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Acorn Financial Advisory Services Inc. ADV lifted its stake in shares of Pfizer by 32.8% in the 4th quarter. Acorn Financial Advisory Services Inc. ADV now owns 9,288 shares of the biopharmaceutical company's stock valued at $246,000 after purchasing an additional 2,292 shares during the last quarter. Finally, Aptus Capital Advisors LLC lifted its stake in shares of Pfizer by 124.0% in the 4th quarter. Aptus Capital Advisors LLC now owns 223,203 shares of the biopharmaceutical company's stock valued at $5,922,000 after purchasing an additional 123,543 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PFE shares. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Price Performance

Shares of PFE stock opened at $24.30 on Friday. The stock has a 50 day moving average price of $23.42 and a 200 day moving average price of $24.85. The firm has a market capitalization of $138.18 billion, a P/E ratio of 17.61, a P/E/G ratio of 0.88 and a beta of 0.57. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. During the same period last year, the business posted $0.82 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.08%. Pfizer's payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.